United BioPharma’s UB-421 suppresses HIV viremia in Phase II

United BioPharma said UB-421 as monotherapy maintained viral suppression for up to 16 weeks without viral rebound in all HIV-1 patients who paused their antiretroviral therapy (ART) regimens in a Phase II trial. UB-421 is a humanized IgG1 mAb against CD4 that blocks HIV entry into CD4₊ T cells.

The open-label, Taiwanese trial enrolled 29 HIV-1 patients whose infection was well controlled by ART to receive eight IV infusions of UB-421 at 10 mg/kg every week or at 25 mg/kg every two weeks after discontinuing ART. Data were published in The New England Journal of Medicine...